Patent Applications for AFINITOR DISPERZ

See Plans and Pricing

« Back to Dashboard

US Patent Applications for AFINITOR DISPERZ

Subscribe to access the full database, or Start Trial
US Patent Application	Patent No.	Title	Patent Filing Date	Patent Application Status	Status Updated
Start Trial	Start Trial	Delivery of therapeutic capable agents	2001-11-01	Abandoned -- Failure to Respond to an Office Action	2008-11-10
Start Trial	Start Trial	COMPOUNDS AND METHODS FOR TREATING TRANSPLANT REJECTION	2001-10-25	Patent Expired Due to NonPayment of Maintenance Fees Under 37 CFR 1.362	2012-01-30
Start Trial	Start Trial	Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection	2002-06-07	Abandoned -- Failure to Respond to an Office Action	2006-03-20
>US Patent Application	>Patent No.	>Title	>Patent Filing Date	>Patent Application Status	>Status Updated

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.